Earnings Call · Q1 FY2022·2022-05-12

Q1 22EPS +2.94%·Rev n/aQ4 21EPS 0.00%·Rev n/aQ3 21EPS -94.52%·Rev n/aQ2 21EPS +77.50%·Rev n/a⚠ consensus missing

Whitehawk Therapeutics, Inc. WHWK

Andrew Quan — VP of Business Development and Corporate Strategy

Neil Desai — Founder, President and CEO

Brendan Delaney — Chief Operating Officer

Loretta Itri — Head of Clinical Development or similar R&D leadership role

Scott Giacobello — Chief Financial Officer

+9.3%1d on move date+9.4% vs SPY3d+18.6%5d+19.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more WHWK calls or request research access.

More WHWK calls Browse calls Request research access